NASDAQ:XGN Exagen (XGN) Stock Forecast, Price & News $3.15 -0.04 (-1.25%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$3.08▼$3.1750-Day Range$2.36▼$3.4852-Week Range$2.04▼$8.96Volume1,258 shsAverage Volume21,757 shsMarket Capitalization$53.08 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Exagen MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside106.3% Upside$6.50 Price TargetShort InterestHealthy0.07% of Float Sold ShortDividend StrengthN/ASustainability-1.29Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.76) to ($1.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.40 out of 5 starsMedical Sector175th out of 981 stocksMedical Laboratories Industry6th out of 22 stocks 3.4 Analyst's Opinion Consensus RatingExagen has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.50, Exagen has a forecasted upside of 106.3% from its current price of $3.15.Amount of Analyst CoverageExagen has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.07% of the float of Exagen has been sold short.Short Interest Ratio / Days to CoverExagen has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exagen has recently decreased by 54.55%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldExagen does not currently pay a dividend.Dividend GrowthExagen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExagen has received a 70.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Diagnostic test kits" and "Immunology laboratory services for research" products. See details.Environmental SustainabilityThe Environmental Impact score for Exagen is -1.29. Previous Next 0.6 News and Social Media Coverage Search Interest1 people have searched for XGN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Exagen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exagen insiders have not sold or bought any company stock.Percentage Held by Insiders36.80% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.90% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exagen are expected to grow in the coming year, from ($1.76) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exagen is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exagen is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExagen has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Exagen (NASDAQ:XGN) StockExagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.Read More Receive XGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter. Email Address XGN Stock News HeadlinesMay 30, 2023 | finance.yahoo.comExagen Inc. to Participate in the William Blair 43rd Annual Growth Stock ConferenceMay 28, 2023 | americanbankingnews.comExagen Inc. (NASDAQ:XGN) Short Interest Down 54.5% in MayJune 8, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 21, 2023 | americanbankingnews.comCantor Fitzgerald Comments on Exagen Inc.'s FY2023 Earnings (NASDAQ:XGN)May 21, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Exagen Inc. (NASDAQ:XGN) Raised by KeyCorpMay 20, 2023 | americanbankingnews.comWilliam Blair Weighs in on Exagen Inc.'s Q2 2023 Earnings (NASDAQ:XGN)May 17, 2023 | finance.yahoo.comExagen (NASDAQ:XGN) shareholders are up 20% this past week, but still in the red over the last three yearsMay 16, 2023 | msn.comCantor Fitzgerald Reiterates Exagen (XGN) Overweight RecommendationJune 8, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 16, 2023 | markets.businessinsider.comCantor Fitzgerald Reaffirms Their Buy Rating on Exagen (XGN)May 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK) and Exagen (XGN)May 15, 2023 | finance.yahoo.comExagen Inc. Reports First Quarter 2023 ResultsMay 13, 2023 | americanbankingnews.comExagen Inc. (NASDAQ:XGN) Short Interest UpdateMay 13, 2023 | americanbankingnews.comExagen (XGN) to Release Earnings on MondayMay 1, 2023 | finance.yahoo.comExagen Announces Campaign for Lupus Awareness MonthApril 24, 2023 | finance.yahoo.comExagen to Announce First Quarter 2023 Financial Results on May 15, 2023April 19, 2023 | americanbankingnews.comShort Interest in Exagen Inc. (NASDAQ:XGN) Declines By 16.5%March 25, 2023 | americanbankingnews.comQ1 2023 Earnings Forecast for Exagen Inc. Issued By William Blair (NASDAQ:XGN)March 24, 2023 | finance.yahoo.comExagen Inc. (NASDAQ:XGN) Q4 2022 Earnings Call TranscriptMarch 24, 2023 | americanbankingnews.comCantor Fitzgerald Brokers Reduce Earnings Estimates for Exagen Inc. (NASDAQ:XGN)March 24, 2023 | americanbankingnews.comExagen Inc. (NASDAQ:XGN) Forecasted to Post Q1 2023 Earnings of ($0.49) Per ShareMarch 22, 2023 | americanbankingnews.comAnalysts Set Expectations for Exagen Inc.'s Q1 2024 Earnings (NASDAQ:XGN)March 22, 2023 | americanbankingnews.comExagen (NASDAQ:XGN) Given New $5.00 Price Target at BTIG ResearchMarch 22, 2023 | finance.yahoo.comExagen Full Year 2022 Earnings: Revenues Beat Expectations, EPS LagsMarch 20, 2023 | finance.yahoo.comExagen Inc. Reports Fourth Quarter and Full Year 2022 ResultsMarch 20, 2023 | markets.businessinsider.comHere's what Wall Street expects from Exagen's earningsMarch 6, 2023 | finance.yahoo.comExagen to Announce Fourth Quarter and Full Year Financial Results on March 20, 2023See More Headlines XGN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XGN Company Calendar Last Earnings3/20/2023Today6/07/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XGN CUSIPN/A CIK1274737 Webwww.exagen.com Phone760-560-1501FaxN/AEmployees219Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.50 High Stock Price Forecast$7.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+106.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,390,000.00 Net Margins-90.98% Pretax Margin-94.41% Return on Equity-79.22% Return on Assets-41.83% Debt Debt-to-Equity Ratio0.81 Current Ratio7.09 Quick Ratio7.09 Sales & Book Value Annual Sales$45.56 million Price / Sales1.17 Cash FlowN/A Price / Cash FlowN/A Book Value$2.61 per share Price / Book1.21Miscellaneous Outstanding Shares16,850,000Free Float10,650,000Market Cap$53.08 million OptionableNot Optionable Beta1.25 Key ExecutivesMr. Kamal Adawi M.S. (Age 43)MBA, CFO & Corp. Sec. Comp: $609.62kMr. John Aballi (Age 37)CEO, Pres & Director Ryan DouglasInvestors Relations OfficerMr. John Wegener (Age 53)Sr. VP of Sales and Marketing Dr. Andrew L. Concoff FACRM.D., Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory BoardMr. Mark Hazeltine (Age 48)Chief Bus. Officer More ExecutivesKey CompetitorsAkuminNASDAQ:AKUDermTechNASDAQ:DMTKGenetronNASDAQ:GTHPsychemedicsNASDAQ:PMDCentogeneNASDAQ:CNTGView All CompetitorsInsiders & InstitutionsRTW Investments LPBought 26,848 shares on 5/15/2023Ownership: 8.256%Stonepine Capital Management LLCBought 183,032 shares on 5/15/2023Ownership: 6.154%UBS Group AGSold 6,015 shares on 5/12/2023Ownership: 0.776%Cowen AND Company LLCSold 22,470 shares on 5/9/2023Ownership: 5.600%Perkins Capital Management Inc.Bought 7,500 shares on 5/9/2023Ownership: 1.542%View All Insider TransactionsView All Institutional Transactions XGN Stock - Frequently Asked Questions Should I buy or sell Exagen stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XGN shares. View XGN analyst ratings or view top-rated stocks. What is Exagen's stock price forecast for 2023? 4 brokers have issued 1-year price objectives for Exagen's shares. Their XGN share price forecasts range from $5.00 to $7.00. On average, they anticipate the company's share price to reach $6.50 in the next twelve months. This suggests a possible upside of 106.3% from the stock's current price. View analysts price targets for XGN or view top-rated stocks among Wall Street analysts. How have XGN shares performed in 2023? Exagen's stock was trading at $2.40 at the beginning of 2023. Since then, XGN stock has increased by 31.3% and is now trading at $3.15. View the best growth stocks for 2023 here. Are investors shorting Exagen? Exagen saw a decline in short interest in May. As of May 15th, there was short interest totaling 7,000 shares, a decline of 54.5% from the April 30th total of 15,400 shares. Based on an average trading volume of 20,100 shares, the short-interest ratio is currently 0.3 days. Approximately 0.1% of the company's stock are sold short. View Exagen's Short Interest. When is Exagen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our XGN earnings forecast. How were Exagen's earnings last quarter? Exagen Inc. (NASDAQ:XGN) issued its quarterly earnings data on Monday, March, 20th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.71) by $0.13. The firm had revenue of $12.84 million for the quarter, compared to analyst estimates of $8.63 million. Exagen had a negative net margin of 90.98% and a negative trailing twelve-month return on equity of 79.22%. What guidance has Exagen issued on next quarter's earnings? Exagen updated its first quarter 2023 earnings guidance on Tuesday, March, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $9.20 million-$9.70 million, compared to the consensus revenue estimate of $9.33 million. What is Ron Rocca's approval rating as Exagen's CEO? 5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among the company's employees. When did Exagen IPO? (XGN) raised $50 million in an initial public offering on Thursday, September 19th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. Cowen, Cantor and William Blair served as the underwriters for the IPO. What is Exagen's stock symbol? Exagen trades on the NASDAQ under the ticker symbol "XGN." Who are Exagen's major shareholders? Exagen's stock is owned by a number of retail and institutional investors. Top institutional investors include RTW Investments LP (8.26%), Stonepine Capital Management LLC (6.15%), Cowen AND Company LLC (5.60%), Perkins Capital Management Inc. (1.54%), UBS Group AG (0.78%) and First Bank & Trust (0.10%). Insiders that own company stock include Hunt Holdings Limited Partners, James L L Tullis, John Aballi, Mark Hazeltine, Nmsic Co-Investment Fund, LP and Wendy S Johnson. View institutional ownership trends. How do I buy shares of Exagen? Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Exagen's stock price today? One share of XGN stock can currently be purchased for approximately $3.15. How much money does Exagen make? Exagen (NASDAQ:XGN) has a market capitalization of $53.08 million and generates $45.56 million in revenue each year. The company earns $-47,390,000.00 in net income (profit) each year or ($2.52) on an earnings per share basis. How many employees does Exagen have? The company employs 219 workers across the globe. How can I contact Exagen? Exagen's mailing address is 1261 Liberty Way Suite C, VISTA CA, 92081. The official website for the company is www.exagen.com. The company can be reached via phone at 760-560-1501 or via email at ir@exagen.com. This page (NASDAQ:XGN) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.